<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="12414" end="12418" sStart="12343" offset="71" sid="r7.1.use.v.0462" wn="1" wnkey="use%2:34:01::" text="The NMU-induced rat model of mammary tumorigenesis is widely used for chemoprevention studies, and yields rapid development of hormonally responsive mammary tumors with 100% incidence [ 2, 4, 18]." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="39081" end="39091" sStart="null" offset="127" sid="r8.suggest.v.0048" wn="3" wnkey="suggest%2:32:02::" text="In the colon, loss of the type II TGF-? receptor occurs at the late adenoma to carcinoma transition [ 49], suggesting that early premalignant lesions retain TGF-? responsiveness and would be amenable to interventions that enhance TGF-? activity." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="27500" end="27508" sStart="null" offset="5" sid="r8.suggest.v.0031" wn="3" wnkey="suggest%2:32:02::" text="This suggests that there was minimal toxicity associated with the chemopreventive intervention, except in the tamoxifen + 4-HPR group, in which mild toxicity was observed." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="39081" end="39091" sStart="null" offset="127" sid="r8.suggest.v.0048" wn="3" wnkey="suggest%2:32:02::" text="In the colon, loss of the type II TGF-? receptor occurs at the late adenoma to carcinoma transition [ 49], suggesting that early premalignant lesions retain TGF-? responsiveness and would be amenable to interventions that enhance TGF-? activity." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="27500" end="27508" sStart="null" offset="5" sid="r8.suggest.v.0031" wn="3" wnkey="suggest%2:32:02::" text="This suggests that there was minimal toxicity associated with the chemopreventive intervention, except in the tamoxifen + 4-HPR group, in which mild toxicity was observed." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="1838" end="1846" sStart="null" offset="24" sid="r8.suggest.v.0448" wn="3" wnkey="suggest%2:32:02::" text="This strongly suggests that interventions that enhance TGF-? function early in tumorigenesis could delay or prevent the course of the disease." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="39081" end="39091" sStart="null" offset="127" sid="r8.suggest.v.0048" wn="3" wnkey="suggest%2:32:02::" text="In the colon, loss of the type II TGF-? receptor occurs at the late adenoma to carcinoma transition [ 49], suggesting that early premalignant lesions retain TGF-? responsiveness and would be amenable to interventions that enhance TGF-? activity." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="27500" end="27508" sStart="null" offset="5" sid="r8.suggest.v.0031" wn="3" wnkey="suggest%2:32:02::" text="This suggests that there was minimal toxicity associated with the chemopreventive intervention, except in the tamoxifen + 4-HPR group, in which mild toxicity was observed." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="39081" end="39091" sStart="null" offset="127" sid="r8.suggest.v.0048" wn="3" wnkey="suggest%2:32:02::" text="In the colon, loss of the type II TGF-? receptor occurs at the late adenoma to carcinoma transition [ 49], suggesting that early premalignant lesions retain TGF-? responsiveness and would be amenable to interventions that enhance TGF-? activity." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="27500" end="27508" sStart="null" offset="5" sid="r8.suggest.v.0031" wn="3" wnkey="suggest%2:32:02::" text="This suggests that there was minimal toxicity associated with the chemopreventive intervention, except in the tamoxifen + 4-HPR group, in which mild toxicity was observed." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr273.anc" start="12973" end="12980" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" text="We observed that the histology of the tamoxifen-treated mammary glands differed significantly from control glands when examined after 6 weeks of tamoxifen treatment, &lt;b&gt;showing&lt;/b&gt; fewer terminal end-buds and less tertiary branching." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/bcr273.anc" start="35749" end="35754" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Three months of tamoxifen treatment was &lt;b&gt;shown&lt;/b&gt; to cause a consistent induction in extracellular TGF-? in breast cancer biopsies, when compared with pretreatment biopsies from the same patients [ 23]." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="43707" end="43716" sStart="null" offset="109" sid="r11.recommend.v.0541" wn="1" wnkey="recommend%2:32:01::" text="Given the very limited breast tissue available in clinical chemoprevention trials, we do not recommend testing for TGF-?s as surrogate end-point biomarkers at this time." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="14629" end="14638" sStart="null" offset="87" sid="r11.recommend.v.0540" wn="1" wnkey="recommend%2:32:01::" text="Given the very limited breast tissue available in clinical trials, we do not recommend testing for TGF-?s as a surrogate end-point biomarkers at this time." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="40889" end="40894" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The NMU-induced rat model of mammary tumorigenesis is widely used for chemoprevention studies and yields &lt;b&gt;rapid&lt;/b&gt; development of hormonally responsive mammary tumors with 100% incidence [ 2, 4, 18]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="12459" end="12464" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The NMU-induced rat model of mammary tumorigenesis is widely used for chemoprevention studies, and yields &lt;b&gt;rapid&lt;/b&gt; development of hormonally responsive mammary tumors with 100% incidence [ 2, 4, 18]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="40889" end="40894" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The NMU-induced rat model of mammary tumorigenesis is widely used for chemoprevention studies and yields &lt;b&gt;rapid&lt;/b&gt; development of hormonally responsive mammary tumors with 100% incidence [ 2, 4, 18]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="12459" end="12464" sStart="null" offset="0" sid="null" wn="2" wnkey="rapid%5:00:02:fast:01" text="The NMU-induced rat model of mammary tumorigenesis is widely used for chemoprevention studies, and yields &lt;b&gt;rapid&lt;/b&gt; development of hormonally responsive mammary tumors with 100% incidence [ 2, 4, 18]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="13044" end="13048" sStart="null" offset="0" sid="null" wn="1" wnkey="part%1:24:00::" text="&lt;b&gt;Part&lt;/b&gt; of the chemopreventive efficacy of antiestrogens and retinoids in this model may therefore be due to a generalized decrease in ductal development." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="25287" end="25293" sStart="null" offset="177" sid="null" wn="1" wnkey="normal%3:00:01::" text="In analysis of the full experimental set, for any given antibody all sections were stained at the same time so as to be directly comparable, and a normal mouse embryo section was included as a positive control." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="25287" end="25293" sStart="null" offset="177" sid="null" wn="1" wnkey="normal%3:00:01::" text="In analysis of the full experimental set, for any given antibody all sections were stained at the same time so as to be directly comparable, and a normal mouse embryo section was included as a positive control." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="25287" end="25293" sStart="null" offset="177" sid="null" wn="3" wnkey="normal%3:00:03::" text="In analysis of the full experimental set, for any given antibody all sections were stained at the same time so as to be directly comparable, and a normal mouse embryo section was included as a positive control." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="28572" end="28578" sStart="null" offset="95" sid="r9.normal.j.0283" wn="3" wnkey="normal%3:00:03::" text="This staining pattern is consistent with a role for the TGF-?s in the maintenance of normal mammary homeostasis." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="25287" end="25293" sStart="null" offset="177" sid="null" wn="1" wnkey="normal%3:00:01::" text="In analysis of the full experimental set, for any given antibody all sections were stained at the same time so as to be directly comparable, and a normal mouse embryo section was included as a positive control." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="25287" end="25293" sStart="null" offset="177" sid="null" wn="1" wnkey="normal%3:00:01::" text="In analysis of the full experimental set, for any given antibody all sections were stained at the same time so as to be directly comparable, and a normal mouse embryo section was included as a positive control." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="41222" end="41230" sStart="null" offset="0" sid="null" wn="2" wnkey="maturity%1:26:00::" text="Since sexual &lt;b&gt;maturity&lt;/b&gt; is achieved at approximately 11 weeks of age in rats, this means that the chemopreventive agent is given during a period of active development of the mammary gland." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="41222" end="41230" sStart="null" offset="0" sid="null" wn="2" wnkey="maturity%1:26:00::" text="Since sexual &lt;b&gt;maturity&lt;/b&gt; is achieved at approximately 11 weeks of age in rats, this means that the chemopreventive agent is given during a period of active development of the mammary gland." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="41222" end="41230" sStart="null" offset="0" sid="null" wn="1" wnkey="maturity%1:28:00::" text="Since sexual &lt;b&gt;maturity&lt;/b&gt; is achieved at approximately 11 weeks of age in rats, this means that the chemopreventive agent is given during a period of active development of the mammary gland." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="41222" end="41230" sStart="null" offset="0" sid="null" wn="2" wnkey="maturity%1:26:00::" text="Since sexual &lt;b&gt;maturity&lt;/b&gt; is achieved at approximately 11 weeks of age in rats, this means that the chemopreventive agent is given during a period of active development of the mammary gland." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23417" end="23423" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22520" end="22526" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22724" end="22730" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23417" end="23423" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22520" end="22526" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23417" end="23423" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22520" end="22526" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22724" end="22730" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23548" end="23554" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22520" end="22526" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23417" end="23423" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22520" end="22526" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="22724" end="22730" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 , and TGF-? 3 . Antibodies to TGF-? 1 were raised against a synthetic peptide corresponding to residues 1-30 of the &lt;b&gt;mature&lt;/b&gt; protein in either the Laboratory of Chemoprevention (anti-TGF-? 1 -LC; NIH, Bethesda, MD, USA) or the Collagen Corporation (anti-TGF-? 1 -CC; Palo Alto, CA, USA)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="23548" end="23554" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The LC antibody usually stains intracellular TGF-? 1 , whereas the CC antibody stains extracellular TGF-? 1 . Anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc) was raised to a peptide corresponding to residues 72-99 of the &lt;b&gt;mature&lt;/b&gt; TGF-? 2 . Anti-TGF-? 3 (anti-50-60-? 3 -LC) was raised against residues 50-60 of &lt;b&gt;mature&lt;/b&gt; TGF-? 3 [ 20]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/bcr273.anc" start="4630" end="4636" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="Immunohistochemical staining was done using rabbit polyclonal antibodies raised against synthetic peptides that correspond to regions in the &lt;b&gt;mature&lt;/b&gt; forms of TGF-? 1 , TGF-? 2 and TGF-? 3 : anti-TGF-? 1 -LC and anti-TGF-? 1 -CC [ 19], anti-TGF-? 2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz, CA, USA), and anti-50-60-? 3 -LC [ 20], respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="39816" end="39822" sStart="null" offset="29" sid="r9.level.n.0182" wn="1" wnkey="level%1:07:00::" text="Since locally elevated TGF-? levels may select for TGF-?-resistant cells, and because TGF-?s can have oncogenic effects on the stroma, it may actually be important for the safety profile of chemopreventive agents to demonstrate that they do not increase TGF-? levels in the at-risk breast." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="10958" end="10962" sStart="null" offset="61" sid="r9.late.j.0263" wn="6" wnkey="late%3:00:02::" text="There is considerable evidence to suggest that, at late stages in tumorigenesis, TGF-?s can actually promote the tumorigenic process, particularly if the epithelial cells have lost responsiveness to the growth inhibitory effects of TGF-? by this time [ 9]." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="24606" end="24610" sStart="null" offset="122" sid="r9.full.j.0759" wn="6" wnkey="full%5:00:00:ample:00" text="Optimal antibody concentrations were determined by titration on select samples before analysis of the full experimental set." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="24770" end="24774" sStart="null" offset="141" sid="r9.fold.v.0327" wn="2147483645" wnkey="null" text="Staining was shown to be specific in control experiments in which either the primary antibody was preincubated with a 50-fold molar excess of immunizing peptide before being applied to the section (anti-TGF-? 2 , anti-TGF-? 3 ), or the section was stained with an equivalent concentration of nonimmune rabbit immunoglobulin (anti-TGF-? 1 -LC, anti-TGF-? 1 -CC, and anti-LTBP)." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="17972" end="17978" sStart="null" offset="161" sid="r8.family.n.0838" wn="3" wnkey="family%1:14:04::" text="Provocative mechanistic connections have been made between the steroid hormone superfamily, including the SERMS and retinoids, and the TGF-? family of multifunctional growth factors." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="6995" end="7006" sStart="null" offset="63" sid="r11.combination.n.0973" wn="1" wnkey="combination%1:14:00::" text="None of the chemopreventive agents used, alone or in combination, were found to affect expression of any of the TGF-? isoforms or the LTBP in either ductal epithelium or periductal stroma after 6 weeks of chemopreventive intervention (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="26563" end="26574" sStart="null" offset="33" sid="r11.combination.n.0829" wn="1" wnkey="combination%1:14:00::" text="Tamoxifen, alone or in combination with retinoids, decreased tumor incidence by more than 70% by the end of the study, whereas 9cRA alone decreased it by 50%." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="6272" end="6283" sStart="null" offset="33" sid="r11.combination.n.0311" wn="1" wnkey="combination%1:14:00::" text="Tamoxifen, alone or in combination with retinoids, decreased tumor incidence by more than 70% by the end of the study, whereas 9cRA alone decreased it by 50%." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="27308" end="27319" sStart="null" offset="216" sid="r11.combination.n.0257" wn="1" wnkey="combination%1:14:00::" text="The mean weights of the rats in the various experimental groups differed by less than 10% from those of rats not treated with a chemopreventive agent, except for the rats treated with a combination of tamoxifen and 4-HPR, in which the mean weight was approximately 15% lower than the that in untreated group by the end of the study (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/bcr273.anc" start="28683" end="28694" sStart="null" offset="63" sid="r11.combination.n.0522" wn="7" wnkey="combination%1:04:00::" text="None of the chemopreventive agents used, alone or in combination, were found to affect expression of any of the TGF-? isoforms or the LTBP in either ductal epithelium or periductal stroma after 6 weeks of chemopreventive intervention (Fig." />
  </sentences>
</list>